Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.72 USD | -0.58% | +2.13% | -8.95% |
May. 10 | Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering | MT |
May. 08 | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
Financials (USD)
Sales 2024 * | 695M | Sales 2025 * | 760M | Capitalization | 1.43B |
---|---|---|---|---|---|
Net income 2024 * | 58M | Net income 2025 * | 82M | EV / Sales 2024 * | 2.34 x |
Net Debt 2024 * | 196M | Net cash position 2025 * | 49.54M | EV / Sales 2025 * | 1.82 x |
P/E ratio 2024 * |
25.2
x | P/E ratio 2025 * |
16.1
x | Employees | 712 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.74% |
Latest transcript on Pacira BioSciences, Inc.
1 day | -0.58% | ||
1 week | +2.13% | ||
Current month | +17.03% | ||
1 month | +17.70% | ||
3 months | +2.50% | ||
6 months | +15.10% | ||
Current year | -8.95% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Lee
CEO | Chief Executive Officer | 56 | Jan. 01 |
Charles Reinhart
DFI | Director of Finance/CFO | 63 | 11-10-31 |
Jonathan Slonin
CTO | Chief Tech/Sci/R&D Officer | 49 | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Pace
BRD | Director/Board Member | 76 | 08-05-31 |
Paul Hastings
CHM | Chairman | 64 | 11-06-01 |
Andreas Wicki
BRD | Director/Board Member | 64 | 06-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 25 M€ | -2.18% | - | |
0.18% | 43 M€ | +3.56% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 30.72 | -0.58% | 453,283 |
24-05-21 | 30.9 | +0.95% | 968,628 |
24-05-20 | 30.61 | -0.68% | 680,309 |
24-05-17 | 30.82 | -2.19% | 478,755 |
24-05-16 | 31.51 | +4.75% | 757,531 |
Delayed Quote Nasdaq, May 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.95% | 1.43B | |
+37.74% | 723B | |
+34.65% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+17.11% | 244B | |
+9.99% | 208B | |
-4.09% | 205B | |
+7.43% | 166B |
- Stock Market
- Equities
- PCRX Stock